Cardiol Therapeutics (NASDAQ:CRDL) Now Covered by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Cardiol Therapeutics (NASDAQ:CRDL) in a research note issued to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $9.00 price target on the stock. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q1 2024 earnings at ($0.06) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.43 EPS.

Cardiol Therapeutics Price Performance

Shares of Cardiol Therapeutics stock opened at $1.76 on Monday. The firm has a market cap of $120.17 million, a PE ratio of -5.33 and a beta of 0.95. Cardiol Therapeutics has a 12-month low of $0.55 and a 12-month high of $2.17. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $1.70 and its two-hundred day simple moving average is $1.20.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.09) earnings per share (EPS) for the quarter. As a group, equities analysts expect that Cardiol Therapeutics will post -0.31 EPS for the current year.

Institutional Investors Weigh In On Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Laird Norton Trust Company LLC lifted its stake in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 63.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,000 shares of the company’s stock after purchasing an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. 12.49% of the stock is owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.